A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
Conditions
Obesity
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Chambliss Clinical Trials, LLC, Montgomery, Alabama, United States
FDRC, Costa Mesa, California, United States
Los Angeles Institute for Metabolic Research, Los Angeles, California, United States
Encore Medical Research LLC, Hollywood, Florida, United States
South Broward Research LLC, Miramar, Florida, United States
West Orange Endocrinology, Ocoee, Florida, United States
Cedar-Crosse Research Center, Chicago, Illinois, United States
Great Lakes Clinical Trials, Chicago, Illinois, United States
Midwest Inst For Clin Res, Indianapolis, Indiana, United States
L-MARC Research Center, Louisville, Kentucky, United States
Endo And Metab Cons, Rockville, Maryland, United States
StudyMetrix Research LLC, City of Saint Peters, Missouri, United States
Great Lakes Medical Research, Westfield, New York, United States
KDCILM, LLC & Accellacare US, Inc., Wilmington, North Carolina, United States
Family Practice Center of Wadsworth Inc., Wadsworth, Ohio, United States
UPA Ctr Weight and Eating Dis, Philadelphia, Pennsylvania, United States
Clinical Res Collaborative, Cumberland, Rhode Island, United States
Holston Medical Group_Bristol, Bristol, Tennessee, United States
Holston Medical Group, Kingsport, Tennessee, United States
Clinical Research Associates, Nashville, Tennessee, United States
PlanIt Research, PLLC, Houston, Texas, United States
Pinnacle Clinical Research, San Antonio, Texas, United States
National Clin Res Inc., Richmond, Virginia, United States
Rainier Clin Res Ctr Inc, Renton, Washington, United States
Isis Clinical Res. Ctr P.S.C., Guaynabo, Puerto Rico
Study leads
Clinical Transparency (dept. 2834)
Study Director
Novo Nordisk A/S